Cepharanthine Targeting HLA-DR3 to Block Autoimmune Beta Cell Attack
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Type 1 diabetes (T1D) are inadequate, with no curative or preventive therapies available to reverse or prevent the autoimmune attack on pancreatic beta cells, leading to insulin deficiency and hyperglycemia, and existing immune therapies are not targeted, causing global immune suppression and significant side effects.
Innovation Solution
Administration of cepharanthine or its pharmaceutically acceptable salts, solvates, or derivatives to subjects with the human leucocyte antigen class II, DR3 allele (HLA-DR3) genotype to block the HLA-DR3 antigen binding pocket, thereby preventing autoimmune attacks on beta cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-targeted immune therapies are used to treat T1D, then the autoimmune attack on beta cells is suppressed, but global immune suppression and significant side effects occur
Solution Approach 1:
The patent applies local quality by designing a targeted therapy that specifically blocks HLA-DR3, the human leucocyte antigen class II allele associated with T1D susceptibility. This selective blocking mechanism allows the therapy to suppress autoimmune attack on beta cells while preserving other immune functions, thereby eliminating global immune suppression and reducing side effects associated with non-targeted immune therapies.
2Reliability
If lifelong insulin replacement is used to treat T1D, then insulin deficiency is corrected, but the treatment is challenging and insufficient to achieve glycemic targets
Solution Approach 1:
The patent extracts the root cause of T1D by targeting and blocking the HLA-DR3 antigen presentation pathway, which is responsible for triggering the autoimmune attack on beta cells. This approach removes the underlying autoimmune mechanism rather than merely managing symptoms through insulin replacement, potentially leading to disease reversal or prevention and eliminating the need for lifelong insulin therapy.
3Duration of action of moving object
If existing immune therapies are used to delay disease onset or slow progression, then disease progression is reduced, but the therapies are not targeted and cause significant side effects
Solution Approach 1:
The patent applies parameter changes by transitioning from non-specific immune suppression to a targeted blocking mechanism at the HLA-DR3 antigen presentation level. This parameter change in the therapeutic mechanism allows for disease progression modulation while minimizing harmful side effects, as the therapy specifically interferes with the autoimmune response pathway rather than broadly suppressing the immune system.
Data Source
AI summary
This disclosure provides methods of treating and/or preventing type 1 diabetes (T1D) and/or a syndrome including type 1 diabetes and autoimmune thyroiditis in a subject. The methods include administering a therapeutically effective amount of cepharanthine or a pharmaceutically acceptable salt, solvate or derivative thereof to the subject, wherein the subject has a human leucocyte antigen class II, DR3 allele (HLA-DR3) genotype.